SEER logo

Seer, Inc.

SEER
Healthcare|Biotechnology|US
$1.63
+0.00 (+0.00%)
Tangible Book / Share
$4.09
Cash / Share
$2.77

About

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

Stock Price

-24.5%(1Y)
1M
-24.9%
3M
-24.9%
6M
-12.8%
YTD
-10.9%
1Y
-22.0%
3Y
+0.0%
5Y
-95.5%

Pipeline Summary

3 total trials
1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Completed: 3

Key Facts

Market Cap$90.3M
Employees124 (-7% YoY)
CEOOmid C. Farokhzad
IPO DateDec 4, 2020
Beta1.45
52-Week Range$1.55 – $2.38
Avg Volume830,515
ExchangeNASDAQ
Websiteseer.bio

Ownership

Float72.3%
Shares Outstanding55.4M

Recent Insider Trades

Endweiss CharlesAWARD
Nov 2, 202635,000 shares
Endweiss CharlesAWARD
Nov 2, 202665,000 shares @ $1.73
Endweiss CharlesOTHER
Oct 1, 20260 shares
Endweiss CharlesOTHER
Oct 1, 20260 shares
Endweiss CharlesOTHER
Oct 1, 20260 shares

Peers

ANEBAnebulo Pharmaceuticals, Inc.
$11.2M
ANTXAN2 Therapeutics, Inc.
$150.9M
CCCCC4 Therapeutics, Inc.
$381.4M
CGEMCullinan Therapeutics, Inc.
$695.1M
FHTXFoghorn Therapeutics Inc.
$111.1M
GBIOGeneration Bio Co.
$36.0M
GLUEMonte Rosa Therapeutics, Inc.
$901.8M
HCWBHCW Biologics Inc.
$354.6K
Data last updated: Nov 9, 2026, 04:33 AM